Roivant Sciences (ROIV) Gross Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Gross Margin came in at 83.19% in Q4 2025, down 1353.0% YoY from 6.64% in Q4 2024, and down 10.49% on a QoQ basis from 92.93% in Q3 2025.
Powered by 
Analysis
Roivant Sciences (ROIV) Gross Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Gross Margin data on file, last reported at 83.19% in Q4 2025.
- Quarterly Gross Margin fell 1353.0% year-over-year to 83.19% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 93.75% (down 182.0% YoY) and the FY2026 annual result came in at 84.44%, down 1242.0% from the prior year.
- Gross Margin retreated to 83.19% in Q4 2025, from 92.93% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 97.33% in Q2 2024 to a low of 54.38% in Q3 2021.
- A 5-year average of 83.81% and a median of 90.41% in 2021 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin plunged 3037 bps — and 2023, when it jumped 2294 bps.
- Tracing ROIV's Gross Margin over 5 years: stood at 81.53% in 2021, then retreated by 10 bps to 73.59% in 2022, then increased by 28 bps to 94.08% in 2023, then climbed by 3 bps to 96.71% in 2024, then retreated by 14 bps to 83.19% in 2025.
- The last three Gross Margin figures came in at 83.19% (Q4 2025), 92.93% (Q3 2025), and 92.9% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | 80.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80.31% |
| Dec 31, 2025 | 83.19% |
| Sep 30, 2025 | 92.93% |
| Jun 30, 2025 | 92.90% |
| Dec 31, 2024 | 96.71% |
| Sep 30, 2024 | 94.77% |
| Jun 30, 2024 | 97.33% |
| Dec 31, 2023 | 94.08% |
| Sep 30, 2023 | 93.89% |
| Jun 30, 2023 | 80.51% |
| Dec 31, 2022 | 73.59% |
| Sep 30, 2022 | 70.95% |
| Jun 30, 2022 | 60.04% |
| Dec 31, 2021 | 81.53% |
| Sep 30, 2021 | 54.38% |
| Jun 30, 2021 | 90.41% |
| Dec 31, 2020 | 88.10% |
| Sep 30, 2020 | 45.96% |
| Jun 30, 2020 | 88.58% |